文献速递呼吸危重症与机械通气呼吸道感染

造血干细胞移植后肺损伤预测模型:多中心队列研究

Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

该多中心队列研究基于2450例造血干细胞移植患者,开发并验证了一个22分预测模型,用于识别移植后急性呼吸衰竭高风险患者。模型在训练队列中预测ARDS的C统计量为0.905,验证队列为0.841,对机械通气需求的预测也表现良好。

要点

  • 22分模型整合移植前、移植后及入院早期(<24小时)预测因子,各占11分。
  • 训练队列预测ARDS的C统计量0.905(95%CI 0.870-0.941),验证队列0.841(95%CI 0.782-0.900)。
  • 模型对侵入性或无创通气需求的预测在训练和验证队列中C统计量分别为0.863和0.872。

核心结论

  • 包含移植前、移植后及入院早期数据的预测模型可可靠预测造血干细胞移植后急性呼吸衰竭。

研究设计与样本

  • 训练队列来自罗切斯特MN(888例患者,1718次住院),验证队列来自斯科茨代尔AZ或杰克逊维尔FL(470例患者,1005次住院)。

主要发现

  • 共2450例患者接受干细胞移植,开发了22分预测模型,其中11分来自院前预测因子,11分来自移植后或入院早期(<24小时)预测因子。
  • 训练队列预测ARDS的C统计量为0.905(95%CI 0.870-0.941),预测侵入性机械通气和/或无创通气需求的C统计量为0.863(95%CI 0.828-0.898)。
  • 验证队列在人口学、医学和血液学特征上差异显著,预测ARDS的C统计量为0.841(95%CI 0.782-0.900),预测通气需求的C统计量为0.872(95%CI 0.831-0.914)。

临床怎么用

  • 该模型可用于识别造血干细胞移植后急性呼吸衰竭高风险患者,有助于纳入临床研究以更好地理解、预防和治疗移植后呼吸衰竭综合征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Pulmonary complications contribute significantly to nonrelapse mortality following hematopoietic stem cell transplantation (HCT). Identifying patients at high risk can help enroll such patients into clinical studies to better understand, prevent, and treat posttransplantation respiratory failure syndromes. Objectives: To develop and validate a prediction model to identify those at increased risk of acute respiratory failure after HCT. Methods: Patients underwent HCT between January 1, 2019, and December 31, 2021, at one of three institutions. Those treated in Rochester, MN, formed the derivation cohort, and those treated in Scottsdale, AZ, or Jacksonville, FL, formed the validation cohort. The primary outcome was the development of acute respiratory distress syndrome (ARDS), with secondary outcomes including the need for invasive mechanical ventilation (IMV) and/or noninvasive ventilation (NIV). Predictors were based on prior case-control studies. Measurements and Main Results: Of 2,450 patients undergoing stem cell transplantation, there were 1,718 hospitalizations (888 patients) in the training cohort and 1,005 hospitalizations (470 patients) in the test cohort. A 22-point model was developed, with 11 points from prehospital predictors and 11 points from posttransplantation or early (<24-h) in-hospital predictors. The model performed well in predicting ARDS (C-statistic, 0.905; 95% confidence interval [CI], 0.870-0.941) and the need for IMV and/or NIV (C-statistic, 0.863; 95% CI, 0.828-0.898). The test cohort differed markedly in demographic, medical, and hematologic characteristics. The model also performed well in this setting in predicting ARDS (C-statistic, 0.841; 95% CI, 0.782-0.900) and the need for IMV and/or NIV (C-statistic, 0.872; 95% CI, 0.831-0.914). Conclusions: A novel prediction model incorporating data elements from the pretransplantation, posttransplantation, and early in-hospital domains can reliably predict the development of post-HCT acute respiratory failure.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Herasevich S, Schulte PJ, Hogan WJ, et al. Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study. Am J Respir Crit Care Med. 2024. PMID: 38051944. doi:10.1164/rccm.202308-1524OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。